View all news

ResMed AirFit P30i, N30i CPAP Masks Earn Good Design Australia Awards

07/11/2019
Medical device leader’s mask design “perfectly executed,” judges say

SYDNEY, July 11, 2019 – ResMed (NYSE: RMD, ASX: RMD) today received Good Design Australia Awards in the Product Design category for achieving the highest level of design and innovation with its two latest CPAP masks, AirFit N30i and AirFit P30i.

Selected from among nearly 700 entries, the nasal AirFit N30i and nasal pillows AirFit P30i are the first ResMed masks with a tube-up connection, allowing wearers to move and sleep in any position. Both masks fit at least 90 percent of wearers with only two frame sizes each.

“Overall, this is a robust piece of design that has been perfectly executed,” said the Good Design Awards Jury. “Care and detail were taken in the material selection for comfort and ease of fitment. They’re good examples of the understanding of the user in the context, and a very sophisticated tooling technique for the spring hinge that accommodates different head shapes, and also the soft nose piece.”

The 30 Series masks are just the latest of ResMed’s Good Design winners; in 2017, ResMed earned four awards for its AirFit N20 nasal mask, AirFit F20 full face mask, and AirTouch F20 full face mask with memory foam cushion, plus AirMini, the world’s smallest CPAP machine.

“We’re honored that Good Design Australia has once again chosen ResMed products as the standard for medical device design,” said Mark Buckley, ResMed’s vice president of sleep product development. “We continue to redefine that standard for the sake of patients’ comfort and overall health, as well as the efficiency of ResMed’s distribution partners. Their continued trust in ResMed is our greatest reward.”

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.

# # #

MEDIA: Jayme Rubenstein, 858.836.6798, news@resmed.com | INVESTORS: Amy Wakeham, 858.836.5000, investorrelations@resmed.com

Multimedia Files:

View all news